Physician profile
Micha Lanier
NPI 1134726599
$9,004.81
in general payments reported to CMS, 2019-2025
21 companies · $2,912 in 2025
The $2,912 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $815 · 2023: $2,398 · 2024: $2,880 · 2025: $2,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,178 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,177.81 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,714.24 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,389.18 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,084.44 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $571.29 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $551.07 | 2022-2025 | Auvelity |
| Alkermes, INC. | $502.45 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $501.14 | 2022-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $387.80 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $374.50 | 2022-2025 | Azstarys |
| Tris Pharma INC | $371.04 | 2022-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Janssen Pharmaceuticals, INC | $290.65 | 2023-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $260.53 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $259.97 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $227.19 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $147.68 | 2023-2025 | Adzenys Xr-Odt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $97.92 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $94.99 | 2022-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $67.45 | 2025 | |
| Ironshore Pharmaceuticals INC. | $62.46 | 2023-2024 | Jornay Pm |
| Avion Pharmaceuticals | $26.99 | 2023 | Methylphenidate Hydrochloride |
| Vertical Pharmaceuticals, LLC | $21.83 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micha Lanier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.